Adakveo Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limited treatment options for sickle cell disease, high burden of vaso occlusive crises, approval of novel biologic therapies, increasing awareness of disease complications, specialist hematology adoption.

The growth in the forecast period can be attributed to growth in sickle cell patient population, expansion of access programs, increased focus on preventive therapies, rising orphan drug investments, improved clinical guidelines adoption. Major trends in the forecast period include rising use of targeted therapies in sickle cell disease, growing focus on vaso occlusive crisis prevention, increased adoption of p selectin inhibitors, expansion of disease modifying treatments, improved long term management of rare blood disorders.

The growing prevalence of sickle cell disease is expected to drive the growth of the adakveo market in the coming years. Sickle cell disease refers to a group of inherited blood disorders caused by abnormal hemoglobin, known as hemoglobin S, within red blood cells. The rising prevalence of sickle cell disease is linked to factors such as higher birth rates in regions where malaria is endemic, hereditary transmission patterns, and improved survival rates resulting from advancements in medical care, which enable more individuals to live longer with the condition. Adakveo supports patients with sickle cell disease by lowering the frequency of vaso-occlusive crises, which are painful events caused by restricted blood flow in small vessels, through its selective inhibition of sickle cell adhesion to blood vessel walls, thereby enhancing blood flow and reducing the symptoms associated with this severe condition. For instance, in July 2024, according to the Pennsylvania Bar Institute, a US-based organization, approximately 7.74 million people were living with sickle cell disease in 2021, and the number of newborns diagnosed each year is projected to rise from 275,000 in 2021 to more than 400,000 by 2050. Therefore, the increasing prevalence of sickle cell disease is contributing to the expansion of the adakveo market.

The growing emphasis on targeted therapies is expected to propel the growth of the adakveo market going forward. Targeted therapies are treatments designed to precisely target and block specific molecular abnormalities involved in cancer and other diseases, thereby enhancing treatment accuracy while minimizing damage to healthy cells. The increased focus on targeted therapies is driven largely by advancements in precision medicine, which enable personalized and more effective treatment approaches based on individual genetic characteristics. Adakveo strengthens targeted treatment strategies by specifically binding to P-selectin, thereby reducing vaso-occlusive crises in patients with sickle cell disease. By addressing a key mechanism involved in inflammation and cell adhesion, it improves treatment precision, leading to fewer pain episodes and improved clinical outcomes. For instance, in December 2024, according to the American Society of Gene & Cell Therapy, a US-based non-profit medical and scientific organization, the Food and Drug Administration approved six gene therapy products in 2023, compared with five approvals in 2022. Therefore, the increasing focus on targeted therapies is driving the growth of the adakveo market.

An increase in healthcare expenditure is expected to support the growth of the adakveo market in the future. Healthcare expenditure refers to the financial investments made by governments, private insurers, and individuals to enhance and expand healthcare services. Higher healthcare spending supports the adoption of Adakveo by enabling greater investment in innovative treatments for sickle cell disease and improving patient access to this targeted therapy, which helps reduce the frequency of vaso-occlusive crises and improves quality of life, particularly in regions with well-funded healthcare systems and access to specialty medicines. For instance, in May 2023, according to the Office for National Statistics, a UK-based government department, healthcare spending in the UK increased by 5.6% from 2022 to 2023, compared with 0.9% growth in 2022, reaching approximately $317.63 billion (£292 billion) in 2023. Thus, rising healthcare expenditure is driving the growth of the adakveo market.

Major companies operating in the adakveo market are Novartis AG.

North America was the largest region in the adakveo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adakveo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adakveo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the adakveo market by increasing costs related to imported monoclonal antibody ingredients, infusion related consumables, and cold chain logistics. These impacts are more evident in regions dependent on imported biologics, including asia pacific and parts of latin america. Hospital and specialty clinic procurement budgets have experienced pricing pressures due to higher landed costs. However, tariffs have encouraged regional biologics packaging and distribution investments. This supports supply continuity and improves long term access to sickle cell therapies.

The adakveo market research report is one of a series of new reports that provides adakveo market statistics, including adakveo industry global market size, regional shares, competitors with a adakveo market share, detailed adakveo market segments, market trends and opportunities, and any further data you may need to thrive in the adakveo industry. This adakveo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Adakveo is a prescription medication used to prevent vaso-occlusive crises in patients with sickle cell disease. It works by targeting P-selectin to reduce blood cell adhesion and inflammation. Adakveo is prescribed to decrease the frequency of painful vaso-occlusive episodes in individuals with sickle cell disease.

The main indications in the adakveo market include sickle cell disease in both adult and pediatric patients, as well as the prevention of vaso-occlusive crises. Sickle cell disease is a group of inherited blood disorders characterized by the presence of abnormal hemoglobin, known as hemoglobin S. The drug can be administered through routes such as intravenous injection, infusion therapy, and oral administration, and is distributed via hospital pharmacies, retail pharmacies, and online pharmacies. End users include hospitals, clinics, ambulatory care centers, and home care settings.

The adakveo market consists of sales of infusion sets, vials, injectable crizanlizumab, needles, and syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.